pretickt

Is ABBV a good stock to buy?

AbbVie Inc. · end-of-day data as of Nov 13, 2026

AbbVie
ABBV · $521B
$295.03+0.2%
Nov 13, 2026 · close
$260$280SepOctNov9:3016:003 months +14.6%Nov 13 · close
▲ 6
  • ConsensusBuy · 29
  • P/E vs own-36.5%
  • News
  • Trendbullish
  • MAs4 of 4
  • Sector▲ +15.9%
Neutral
  • Earnings in82d
  • P/E50.6x
  • RSI63
  • Support-1.0%
  • Off 52w high-2.6%
  • Volume0.6x
  • Bollingerupper half
  • FCF yield+3.6%
  • PT$306.88 +4.0%
  • 52w range$191–$303
  • ATR+2.3%
  • Off ATH-2.6%
▼ 3
  • P/E vs sector+57.1%
  • Insiders-$11.93M
  • MACD-0.34

Updates with the 15-min delayed price. Not a forecast or investment advice.

Is AbbVie a good stock to buy?

AbbVie is strong on 1 of the 5 questions about the business. The price is low: 50.6 times its earnings, below its 3-year median of 72.4 (Nov 13, 2026). pretickt does not say whether to buy or sell.

  1. Demand steady
  2. Advantage some edge
  3. Economics profits steady
  4. Execution delivers
  5. Fragility some risks
  6. Price below its usual
DemandDo people want more of what it sells?steady

ABBV sales growth revenue growth

+2%a year, for the last 3 years

AbbVie's sales grew 2% a year for 3 years, to $61.16B in fiscal 2025.

ABBV analysts' forecast revenue estimates

+11%the sales they expect next fiscal year, on the last

Analysts expect AbbVie's sales to grow 11% to $67.69B in fiscal 2026 (17 analysts).

ABBV competitors

pretickt analysis+11%its sales in 12 months, on a year before

AbbVie's sales grew 11% in the 12 months to Sep 30, 2026, faster than Amgen (+8%), Gilead (+7%) and Merck (+5%).

ABBV customers' spending

pretickt analysis+23%what its customers invest, on a year before

Cencora, Cardinal Health and McKesson, customers of AbbVie, spent 23% more on capital in their latest quarter (to Sep 30, 2026) than a year before.

Advantage moatIs it hard to copy?some edge

ABBV margin on each sale gross margin

76%left after making the product

AbbVie kept 76% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 77%.

EconomicsDoes it make good money?profits steady

ABBV cash generated free cash flow

$18.87Bcash left after investing, last 12 months

AbbVie generated $18.87B of free cash flow in the 12 months to Sep 30, 2026, more than its reported profit.

ABBV profit per share

-1%in its last fiscal year

AbbVie's earnings per share fell 1% in fiscal 2025, to $2.37.

ExecutionDoes it deliver what it promises?delivers

ABBV earnings vs estimates

6 of 7quarters above the analysts' estimate

AbbVie beat the analysts' profit estimate in 6 of 7 quarters, the latest on Oct 30, 2026; 1 quarter the sources disagree on is left out.

ABBV insider selling

-$30.85Msold, net, by its executives in 12 months

AbbVie's executives and directors sold a net $30.85M of shares in the 12 months to Nov 13, 2026; none bought.

ABBV number of employees

+4%more people in a year

AbbVie had 57,000 employees at the end of fiscal 2025, 4% more than a year before.

ABBV CEO pay

$32.53Mfor fiscal 2025, 51% of it in stock and options

AbbVie paid its CEO $32.53M for fiscal 2025, 51% of it in stock and options.

Fragility risksCould something break it?some risks

ABBV financial health Altman Z-score

2.7Altman Z-score, safe above 3

AbbVie's Altman Z-score is 2.7 (Nov 13, 2026), between 1.8 and 3, the grey zone.

ABBV quality checks Piotroski score

7 of 9checks passed

AbbVie passes 7 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on long-term debt and new shares.

ABBV biggest customers

76%of sales from its 3 biggest customers

McKesson, Cardinal Health and Cencora made 76% of AbbVie's sales in fiscal 2025.

ABBV shareholders institutional ownership

pretickt analysis
  • Vanguard9.3% ▼
  • BlackRock8.4% ▼
  • State Street4.7% ▲
4,353institutions hold it; the largest sold shares

4,353 institutions hold 76% of AbbVie's shares (Jun 30, 2026); State Street added shares that quarter, Vanguard and BlackRock sold some.

Price valuationIs the price reasonable?below its usual

ABBV price vs profit P/E ratio

50.6×a year's earnings

AbbVie's P/E ratio is 50.6 (Nov 13, 2026), below its 3-year median of 72.4.

ABBV price vs competitors

pretickt analysis50.6×a year's earnings, against its competitors

Investors pay 50.6 times AbbVie's earnings (Nov 13, 2026), more than for Amgen (27.0), less than for Merck (152.3).

ABBV analysts' target price target

+4%to their average target

Analysts' average price target for AbbVie is $307, 4% above the Nov 13, 2026 close of $295.03.

ABBV growth priced in fair value

pretickt analysis+11%a year, for ten years, to be worth the price

At $295.03 a share, AbbVie's free cash flow must grow about 11% a year for ten years to be worth the price (Nov 13, 2026).

What is AbbVie's P/E ratio?

AbbVie's P/E ratio is 50.6 (Nov 13, 2026), below its 3-year median of 72.4. Investors pay 50.6 times AbbVie's earnings (Nov 13, 2026), more than for Amgen (27.0), less than for Merck (152.3).

Who are AbbVie's biggest competitors?

pretickt compares AbbVie with Johnson & Johnson, Merck, Amgen and Gilead. AbbVie's sales grew 11% in the 12 months to Sep 30, 2026, faster than Amgen (+8%), Gilead (+7%) and Merck (+5%).

Are insiders selling AbbVie stock?

AbbVie's executives and directors sold a net $30.85M of shares in the 12 months to Nov 13, 2026; none bought.

Who owns AbbVie stock?

4,353 institutions hold 76% of AbbVie's shares (Jun 30, 2026); State Street added shares that quarter, Vanguard and BlackRock sold some.

How many employees does AbbVie have?

AbbVie had 57,000 employees at the end of fiscal 2025, 4% more than a year before.

Who are AbbVie's biggest customers?

McKesson, Cardinal Health and Cencora made 76% of AbbVie's sales in fiscal 2025. Cencora, Cardinal Health and McKesson, customers of AbbVie, spent 23% more on capital in their latest quarter (to Sep 30, 2026) than a year before.

From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.